This Day On The Street
Continue to site right-arrow
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

AstraZeneca Falls on Drug Delay

Updated from 10:28 a.m. EDT

Shares of AstraZeneca (AZN) skidded Wednesday after the company pushed back its schedule for seeking regulatory approval for an experimental diabetes drug.

At the same time, the company said it was on track to achieve the midpoint of its previous earnings guidance, which had been in the range of $2 to $2.15. The consensus among analysts polled by Thomson First Call was an EPS of $2.08. Analysts had predicted an EPS as high as $2.15 and as low as $1.98

The company's stock dropped $1.14 or 2.8%, to $39.44 on Wednesday.

AstraZeneca said it had not discovered any problems with the drug in question, Galida, which has progressed from phase II clinical studies to phase III testing -- the last step before a drug is submitted to health care regulators. However, the company is extending long-term follow-up clinical studies, citing "worldwide regulatory authority review of the safety and toxicology" of the drug group to which Galida belongs. Follow-up testing will take two years instead of one year, pushing the regulatory application back to 2007.

Galida is part of a class of drugs called PPAR, which analysts have said can be troublesome. For example, Merck (MRK) was working on a PPAR with Japan's Kyorin Pharmaceutical; but Merck halted phase III testing 11 months ago when a safety review program detected rare malignant tumors in mice. "The clinical relevance of these findings in humans is unknown," Merck acknowledged.

Sir Tom McKillop, AstraZeneca's CEO, said Tuesday he had high hopes for Galida and for Cerovive, a stroke treatment. "With Galida, we had over 1,000 patients in our phase II studies, so we've got a lot of experience already," he said in remarks released during an annual meeting with analysts. "Cerovive is already into two big phase III studies. There is a safety monitoring committee ... and they have given no indication of any reason to stop to date."

1 of 2

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!

Markets

DOW 18,030.21 +6.04 0.03%
S&P 500 2,081.88 -0.29 -0.01%
NASDAQ 4,773.4720 +8.0480 0.17%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs